uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Phase I and Pharmacokinetic Evaluation of Intravenous Hyaluronic Acid in Combination with Doxorubicin or 5-Fluorouracil
Show others and affiliations
2005 (English)In: Chemotherapy, ISSN 0009-3157, E-ISSN 1421-9794, Vol. 51, no 2-3, 132-141 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Pre-clinically, hyaluronan (HA) has been demonstrated to systemically target chemotherapeutic drugs to tumours while ameliorating treatment toxicities. This study is a preliminary clinical investigation to determine if HA could be safely used in combination with 5-fluorouracil (5-FU) and doxorubicin (DOX). METHODS: Thirty patients with metastatic cancer were intravenously administered 500 mg/m2 HA in combination with escalating doses of DOX (30-60 mg/m2) or 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle). The effect of pre-administration of 20 mg/m2 of folinic acid on HA/5-FU chemotherapy was also investigated. Patients were randomized to receive either HA/chemotherapy or chemotherapy alone in their first treatment cycle and vice versa for the second cycle. Patients received HA and chemotherapy in all subsequent cycles. RESULTS: Treatment was well tolerated, tumour responses were observed and the co-administration of HA did not alter the pharmacokinetics of clinically relevant doses of 5-FU or DOX. CONCLUSION: High doses of intravenous high-molecular-weight HA can be safely co-administered with clinical doses of chemotherapy without significantly altering the toxicity or pharmacokinetics of the drugs or HA.

Place, publisher, year, edition, pages
2005. Vol. 51, no 2-3, 132-141 p.
Keyword [en]
Adjuvants; Immunologic/administration & dosage/adverse effects/*pharmacokinetics, Adult, Aged, Antineoplastic Agents/administration & dosage/adverse effects/*pharmacokinetics, Comparative Study, Dose-Response Relationship; Drug, Doxorubicin/administration & dosage/adverse effects/*pharmacokinetics, Drug Therapy; Combination, Female, Fluorouracil/administration & dosage/adverse effects/*pharmacokinetics, Humans, Hyaluronic Acid/administration & dosage/adverse effects/*pharmacokinetics, Infusions; Intravenous, Leucovorin/pharmacology, Male, Middle Aged, Neoplasm Metastasis, Neoplasms/*drug therapy/pathology
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-74773DOI: 10.1159/000085621PubMedID: 15886473OAI: oai:DiVA.org:uu-74773DiVA: diva2:102683
Available from: 2005-11-15 Created: 2005-11-15 Last updated: 2013-11-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15886473&dopt=Citation

Search in DiVA

By author/editor
Heldin, Paraskevi
By organisation
Ludwig Institute for Cancer Research
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 195 hits
ReferencesLink to record
Permanent link

Direct link